Company news

Immatics N.V. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

October 9, 2022

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

October 9, 2022

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

September 9, 2022

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

August 22, 2022

Immatics Announces Second Quarter 2022 Financial Results and Business Update

August 8, 2022

Immatics Announces First Quarter 2022 Financial Results and Business Update

June 1, 2022

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

May 17, 2022

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

May 9, 2022

Immatics Announces Full Year 2021 Financial Results and Corporate Update

March 22, 2022

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

December 13, 2021

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

November 15, 2021

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

November 8, 2021

Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

August 9, 2021

Immatics Announces Changes to its Board of Directors

May 25, 2021

Immatics Announces First Quarter 2021 Financial Results and Business Update

May 17, 2021

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

May 10, 2021

Immatics Announces Full Year 2020 Financial Results and Corporate Update

March 29, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

March 16, 2021

Immatics Announces Third Quarter 2020 Financial Results and Business Update

December 1, 2020

Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference

November 9, 2020

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8

October 28, 2020

Immatics Appoints Arnd Christ as Chief Financial Officer

September 28, 2020

Immatics Appoints Biotech Executive Eliot Forster to Board of Directors

September 14, 2020

Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment

September 9, 2020

Immatics Announces Second Quarter 2020 Financial Results and Business Update

September 2, 2020

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs

August 17, 2020

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth

August 5, 2020

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

July 8, 2020

Immatics Announces Completion of Business Combination and Listing on NASDAQ

July 1, 2020

← Newer news releases

Decks

The 5 newest of 54 decks. Every deck is listed under its year.